{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T07:10:19Z","timestamp":1771312219605,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This post hoc analysis investigates the impact of baseline characteristics on the efficacy and safety of oral semaglutide in a Chinese population with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      Chinese participants from the PIONEER 11 and 12 trials with type 2 diabetes aged \u226518\u2009years were randomised to once\u2010daily oral semaglutide 3, 7, or 14\u2009mg, or placebo (PIONEER 11) or sitagliptin 100\u2009mg (PIONEER 12). Changes from baseline in HbA\n                      <jats:sub>1c<\/jats:sub>\n                      and body weight at week 26 were analysed in subgroups according to the following baseline characteristics: age, HbA\n                      <jats:sub>1c<\/jats:sub>\n                      , body mass index, duration of diabetes, and presence of gastrointestinal disease. Adverse events (AEs) by baseline subgroups were also assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 390 (PIONEER 11) and 1084 (PIONEER 12) Chinese participants with type 2 diabetes were evaluated. Most baseline characteristics were similar across the two trials in the different subgroups. Overall, greater reductions in HbA\n                      <jats:sub>1c<\/jats:sub>\n                      and body weight were observed with oral semaglutide versus comparators across the subgroups. A significant difference was observed for change in HbA\n                      <jats:sub>1c<\/jats:sub>\n                      by baseline HbA\n                      <jats:sub>1c<\/jats:sub>\n                      subgroups (\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>int<\/jats:sub>\n                      \u2009&lt;0.05), with greater reductions observed in the subgroups with higher baseline HbA\n                      <jats:sub>1c<\/jats:sub>\n                      . Most AEs were gastrointestinal\u2010related and mild\u2010to\u2010moderate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\/Interpretation<\/jats:title>\n                    <jats:p>\n                      Oral semaglutide reduces HbA\n                      <jats:sub>1c<\/jats:sub>\n                      and body weight across a range of baseline subgroups in a Chinese population with type 2 diabetes without any unexpected additional safety concerns. These results support the use of oral semaglutide in a broad population in clinical practice.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70031","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T10:17:08Z","timestamp":1755857828000},"page":"6386-6394","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the\n                    <scp>PIONEER<\/scp>\n                    11 and 12 randomised controlled trials"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-1598","authenticated-orcid":false,"given":"Linong","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism Peking University People's Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0822-6066","authenticated-orcid":false,"given":"Guoyue","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology The Affiliated Hospital of Jiangsu University  Zhenjiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Shanghai Fifth People's Hospital, Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingjie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Novo Nordisk (Shanghai) Pharma Trading Co., Ltd  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Novo Nordisk (Shanghai) Pharma Trading Co., Ltd  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zewei","family":"Shen","sequence":"additional","affiliation":[{"name":"Novo Nordisk (Shanghai) Pharma Trading Co., Ltd  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00894-y"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01340-x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1144"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00669-4"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00389-7"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-015-0602-9"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dbi17-0013"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12098"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05787-2"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S006"},{"key":"e_1_2_10_13_1","first-page":"16","article-title":"Guidelines for the prevention and treatment of diabetes mellitus in China (2024 edition)","volume":"17","author":"Chinese Society of Diabetes","year":"2025","journal-title":"Chin J Diabetes Mellitus"},{"key":"e_1_2_10_14_1","unstructured":"Novo Nordisk A\/S.Ozempic summary of product characteristics.2020. Accessed July 2025.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ozempic-epar-product-information_en.pdf"},{"key":"e_1_2_10_15_1","unstructured":"Novo Nordisk A\/S.Rybelsus\u00ae (oral semaglutide) Prescribing information.2020. Accessed July 2025.https:\/\/www.novo-pi.com\/rybelsus.pdf"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14054"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06142-3"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06133-4"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20995"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15888"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu14173506"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13086"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP.17.6.906"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13896"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14710"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12872"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S367985"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14244"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70031","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.70031","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T06:22:50Z","timestamp":1771309370000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.70031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/dom.70031"],"URL":"https:\/\/doi.org\/10.1111\/dom.70031","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"2025-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}